These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 35151642)

  • 1. ATRA promotes PD-L1 expression to control gastric cancer immune surveillance.
    Ma ZL; Ding YL; Jing J; Du LN; Zhang XY; Liu HM; He PX
    Eur J Pharmacol; 2022 Apr; 920():174822. PubMed ID: 35151642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.
    Liang Y; Wang W; Zhu X; Yu M; Zhou C
    Sci Rep; 2022 Jun; 12(1):9619. PubMed ID: 35688951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of programmed death ligand 1 (PD-L1) is associated with metastasis and differentiation in gastric cancer.
    He PX; Ma ZL; Han H; Zhang XY; Niu SH; Du LN; Zheng YC; Liu HM
    Life Sci; 2020 Feb; 242():117247. PubMed ID: 31899223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 5. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
    Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
    Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastric cancer mesenchymal stem cells via the CXCR2/HK2/PD-L1 pathway mediate immunosuppression.
    Huang C; Chen B; Wang X; Xu J; Sun L; Wang D; Zhao Y; Zhou C; Gao Q; Wang Q; Chen Z; Wang M; Zhang X; Xu W; Shen B; Zhu W
    Gastric Cancer; 2023 Sep; 26(5):691-707. PubMed ID: 37300724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1
    Li Q; Zhou ZW; Lu J; Luo H; Wang SN; Peng Y; Deng MS; Song GB; Wang JM; Wei X; Wang D; Westover KD; Xu CX
    Mol Ther; 2022 Feb; 30(2):621-631. PubMed ID: 34547468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-PD-L1-modified and ATRA-loaded nanoparticles for immuno-treatment of oral dysplasia and oral squamous cell carcinoma.
    Chen XJ; Zhang XQ; Tang MX; Liu Q; Zhou G
    Nanomedicine (Lond); 2020 Apr; 15(10):951-968. PubMed ID: 32255397
    [No Abstract]   [Full Text] [Related]  

  • 9. Cancer-Associated Fibroblast-Derived IL-8 Upregulates PD-L1 Expression in Gastric Cancer Through the NF-κB Pathway.
    Lou M; Iwatsuki M; Wu X; Zhang W; Matsumoto C; Baba H
    Ann Surg Oncol; 2024 May; 31(5):2983-2995. PubMed ID: 38006530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway.
    Wang TT; Zhao YL; Peng LS; Chen N; Chen W; Lv YP; Mao FY; Zhang JY; Cheng P; Teng YS; Fu XL; Yu PW; Guo G; Luo P; Zhuang Y; Zou QM
    Gut; 2017 Nov; 66(11):1900-1911. PubMed ID: 28274999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pumilio1 regulates NPM3/NPM1 axis to promote PD-L1-mediated immune escape in gastric cancer.
    Wang H; Zhou Z; Zhang J; Hao T; Wang P; Wu P; Su R; Yang H; Deng G; Chen S; Gu L; He Y; Zeng L; Zhang C; Yin S
    Cancer Lett; 2024 Jan; 581():216498. PubMed ID: 38029539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway.
    Lv Y; Zhao Y; Wang X; Chen N; Mao F; Teng Y; Wang T; Peng L; Zhang J; Cheng P; Liu Y; Kong H; Chen W; Hao C; Han B; Ma Q; Zou Q; Chen J; Zhuang Y
    J Immunother Cancer; 2019 Feb; 7(1):54. PubMed ID: 30808413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
    Kim YB; Ahn JM; Bae WJ; Sung CO; Lee D
    Int J Cancer; 2019 Aug; 145(4):916-926. PubMed ID: 30664822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer.
    Shen DD; Pang JR; Bi YP; Zhao LF; Li YR; Zhao LJ; Gao Y; Wang B; Wang N; Wei L; Guo H; Liu HM; Zheng YC
    Mol Cancer; 2022 Mar; 21(1):75. PubMed ID: 35296335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
    Zhang Y; Wang F; Sun HR; Huang YK; Gao JP; Huang H
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2209-2222. PubMed ID: 33891173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis.
    Sun L; Wang Q; Chen B; Zhao Y; Shen B; Wang H; Xu J; Zhu M; Zhao X; Xu C; Chen Z; Wang M; Xu W; Zhu W
    Cell Death Dis; 2018 Sep; 9(9):928. PubMed ID: 30206229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-ɑ signaling.
    Ju X; Zhang H; Zhou Z; Chen M; Wang Q
    Exp Cell Res; 2020 Nov; 396(2):112315. PubMed ID: 33031808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
    Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
    Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions.
    Sasaki S; Nishikawa J; Sakai K; Iizasa H; Yoshiyama H; Yanagihara M; Shuto T; Shimokuri K; Kanda T; Suehiro Y; Yamasaki T; Sakaida I
    Gastric Cancer; 2019 May; 22(3):486-496. PubMed ID: 30264329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.